Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term AKT. Found 11 abstracts

Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 Oct;123(1):19-26.   PMCID: PMC3336961 [Available on 2012/10/1]
Shukla A, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, O'Byrne KJ, Testa JR, Pass HI, Faux SP, Mossman BT. An Extracellular Signal-Regulated Kinase 2 Survival Pathway Mediates Resistance of Human Mesothelioma Cells to Asbestos-Induced Injury. American Journal of Respiratory Cell and Molecular Biology. 2011 Nov;45(5):906-14.   PMCID: PMC3262687
Timakhov RA, Tan YF, Rao M, Liu ZM, Altomare DA, Pei JM, Wiest DL, Favorova OO, Knepper JE, Testa JR. Recurrent Chromosomal Rearrangements Implicate Oncogenes Contributing to T-Cell Lymphomagenesis in Lck-MyrAkt2 Transgenic Mice. Genes Chromosomes & Cancer. 2009 Sep;48(9):786-94.   PMCID: PMC 2739734
Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl CD, Kim SH, Klein-Szanto A, Diehl JA, Herlyn M, El-Deiry W, Rustgi AK. AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene. 2007 Apr;26(16):2353-64.
Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005 Nov 14;24(50):7455-64.
Altomare DA, You HH, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005 Sep 08;24(40):6080-9.
Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005 Nov 14;24(50):7475-81.
Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3 ' kinase/AKT pathways. Oncogene. 2005 Nov;24(50):7443-54.
Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene. 2005 Nov 14;24(50):7391-3.
De Vita G, Berlingieri MT, Visconti R, Castellone MD, Viglietto G, Baldassarre G, Zannini M, Bellacosa A, Tsichlis PN, Fusco A, Santoro M. Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Research. 2000 Jul;60(14):3916-20.
Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes & development. 1997 Mar;11(6):701-13.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term AKT

AKT ACTIVATION phosphatidylinositol 3-kinase TRANSCRIPTION mammalian target asbestos ovarian-cancer tumor suppressor genes mTOR mesothelioma prostate intraepithelial neoplasia akt inhibitor renal angiomyolipomas molecular-cloning protein-kinase-b proliferation cell-growth PKB kinases oxidative stress TUMOR SUPPRESSION KINASE-B b-raf kinase metastatic colorectal-cancer protein-kinase PHOSPHATIDYLINOSITOL 3-KINASE PREIMPLANTATION EMBRYOS FACTOR-I RECEPTOR HIRSCHSPRUNG-DISEASE frequent activation therapeutic target LEUKEMIA EPITHELIAL-CELLS OVARIAN-CANCER ovarian induced apoptosis sv40 malignant mesothelioma mutational analysis receptor PROTEIN-KINASE PKB ONCOGENIC TRANSFORMATION progression GENE E-cadherin Rheb simian-virus-40 platinum-resistant E-CADHERIN EXPRESSION growth-factor-receptor PROGENITOR CELLS CARCINOMA GROWTH-FACTOR-BETA breast-cancer refractory IN-VITRO EGFR mesenchymal transition C-MYC tsc2 gap activity ONCOGENES DIFFERENTIATION TRANSCRIPTION FACTOR EXPRESSION Ovarian clinical trial apoptosis lymphangiomyomatosis resistant prostate-cancer tumor-suppressor gene PI3K pathway cell survival tuberous-sclerosis INSULIN organotypic culture tuberous sclerosis complex gene expression INDUCTION akt activation ARCHITECTURE PKB pathway oncogenes KERATINOCYTES MOUSE CPP32 protein kinase B mammalian target of Rapamycin Circulating tumor cells factor scatter factor CELL-DEATH disease MYC-MEDIATED protein human malignancy C-MYC ONCOGENE INTEGRIN-LINKED KINASE invasion TUMOR-CELLS SMAD-INTERACTING PROTEIN-1 kinase-b GLYCOGEN-SYNTHASE KINASE-3 carcinoma patients epidermal growth factor receptor peripheral-blood FACTOR SNAIL tumor-cell growth growth factors malignant pleural mesothelioma PI3K human pancreatic-cancer oncogene ACTIVATED PROTEIN-KINASE s6 kinase activation pulmonary lymphangioleiomyomatosis metastasis epithelial CANCER PROLIFERATION akt pathway GROWTH CARCINOMA CELL-LINE c-met toxicity differentiation targeted therapy SIGNALING PATHWAY TRANSLOCATIONS APOPTOSIS Myc phosphorylation breast cancers PROTEIN-KINASE-B DEPENDENT KINASE 3-kinase
Last updated on Saturday, June 06, 2020